| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:2373-2375.)
© 2007 American Heart Association, Inc.
Editorial |
From the Department of Cardiovascular Sciences and the Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada.
Correspondence to T.J. Anderson, MD, 1403 29th Street NW, Calgary, AB, T2N 2T9. E-mail todd.anderson{at}calgaryhealthregion.ca
Key Words: Editorials atherosclerosis endothelium risk factors
| Introduction |
|---|
|
|
|---|
Article p 2390
The vascular endothelium is in a unique position to serve as a metric of atherosclerotic risk. The healthy endothelium is antiatherogenic through favorable paracrine effects on vasodilation, inhibition of leukocyte adhesion, platelet aggregation and coagulation, and promotion of healing via progenitor cells.2 However, because of its position in the vascular wall, it is also the target of hemodynamic and biochemical perturbations. This leads to endothelial dysfunction early in the course of the disease, a property that could be exploited for risk evaluation.
| Endothelial Function |
|---|
|
|
|---|
Brachial artery flow-mediated dilation (FMD) has emerged as the most common assessment tool of endothelial function. This response is (1) nitric oxide dependent, (2) abnormal early in the course of the disease process, (3) dysfunctional in response to various cardiovascular risk factors, (4) correlated with abnormalities of coronary endotheliumdependent vasodilation, (5) improved with interventions known to improve cardiovascular outcomes such as statin therapy, (6) relatively inexpensive, (7) noninvasive, and (8) reproducible. Although FMD is not as reproducible as biochemical markers such as cholesterol, the coefficient of variation for repeated measures is acceptable at
20%.
| Prognostic Studies of Endothelial Function |
|---|
|
|
|---|
The prognostic value of abrogated brachial flowmediated vasodilation also has been evaluated. Brachial endothelial dysfunction has been shown to predict restenosis after percutaneous coronary intervention8 and complications after vascular surgery.9 In addition, attenuated brachial flowmediated dilation is an independent predictor of events in the long term in subjects with established atherosclerosis.10,11 In subjects without established vascular disease, the results have been mixed to date.12,13 In the Northern Manhattan Study, 842 subjects (mean age, 67 years) without established vascular disease were followed up for 36 months. Lower FMD predicted events (n=30), but the effect was no longer present in a multivariable model.13 This evidence, although tantalizing, is far from conclusive. Many of the above-mentioned studies have suffered from retrospective designs, variable follow-up, incomplete data, and small numbers of events.
| Current Study |
|---|
|
|
|---|
Event-free survival rates for cardiovascular events were significantly higher in subjects with FMD higher than compared with subjects with FMD less than or equal to the sex-specific medians (78.3% versus 73.6%; P<0.01). After correction for risk factors known to be associated with outcome, FMD remained an independent and significant predictor, with a hazard ratio of 0.91 (95% CI, 0.83 to 0.99) for each unit standard deviation change in FMD. The strongest predictors of an adverse outcome were increasing age, blood pressure, baseline vascular status, and male gender. Similar predictive value was present for the subgroups with and without incident cardiovascular disease at baseline. When FMD was added to the best Cox hazard model, the change in the C statistic was 0.01, suggesting that FMD added only
1% to the prognostic model. Recently, the value of this type of analysis has been questioned because it may underestimate the importance of a new biomarker.
A very interesting finding of the study by Yeboah and colleagues was that subjects with baseline brachial diameter above the gender-specific median values had an increase in event rates. In fact, the predictive value was of the same magnitude as FMD. There was a trend for a similar finding in the recently reported study by Shimbo et al.13 The interpretation of this observation is not clear. It is well known that the strongest predictor of FMD is baseline brachial diameter as a result in part of the mathematics of its calculation but probably also the physiology of shear stress generation in different-sized vessels. This raises the question as to whether the predictive value of FMD in the present study simply reflected baseline diameter differences. Positive remodeling of arteries in response to atherosclerotic risk has been described in the peripheral circulation and may account for this observation.
| Strengths and Unanswered Questions |
|---|
|
|
|---|
Like all good studies, the work of Yeboah and colleagues raises several important questions. First, are the results applicable to younger subjects, in whom one might argue there is greater need to identify novel methods of risk stratification? Several ongoing studies, including 1 from our group, will address this issue in younger populations.13,1517 Second, what is the best measure of vascular health? Is it in fact FMD, or as suggested by Yeboah et al, is FMD simply a measure of baseline diameter? Others have suggested that it may be a measure of microvascular function such as hyperemic velocity or shear stress.18 Modalities other than ultrasound such as pulse arterial tonometry that assess microvascular responses in the extremities are being evaluated. Third, how does a measure of endothelium-dependent vasodilation integrate with other biomarkers or tests of structural atherosclerosis such as carotid intima-media thickness or parameters derived from computed tomography? The present study was unable to address this issue because these measures were not concurrently available. The Multi-Ethnic Study of Atherosclerosis is evaluating multiple markers and should shed further light on this question.19 And finally, will interventions aimed at improving endothelial dysfunction result in improved outcomes, as has been suggested in 1 small study?20
| Clinical Implications |
|---|
|
|
|---|
However, even if tests of endothelial function are not readily incorporated into diagnostic algorithms, the results remain pivotal to clinical medicine. The study by Yeboah and colleagues will solidify measures of endothelium-dependent vasomotion as surrogate markers of disease. As such, these measures can be used to understand the potential importance of novel biochemical or emerging genetic risk factors. The dynamic nature of the measure also allows the study of interventions over a period of months, not years, allowing more rapid evaluation of the novel therapies. This study further justifies the value of the end point.
The study by Yeboah et al contributes significant evidence to the field of vascular biology. Measures of vascular health will further our understanding of the pathophysiology, investigation, and treatment of atherosclerotic vascular disease.
| Acknowledgments |
|---|
Dr Anderson is supported by the Alberta Heritage Foundation for Medical Research (Edmonton, Alberta, Canada).
Disclosures
None.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation. 2003; 108: 20542059.
3. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986; 315: 10461051.[Abstract]
4. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340: 11111115.[CrossRef][Medline] [Order article via Infotrieve]
5. Schachinger V, Britten MB, Zeiher A. Impaired epicardial coronary vasoreactivity predicts for adverse cardiovascular events during long-term follow-up. Circulation. 2000; 101: 18991906.
6. Suwaidi JA, Hamasaki S, Higano ST, Velianou JL, Araujo NA, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 2000; 101: 948954.
7. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation. 2001; 104: 26732678.
8. Patti G, Pasceri V, Melfi R, Goffredo C, Chello M, DAmbrosio A, Montesanti R, Di Sciascio G. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation. 2005; 111: 7075.
9. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation. 2002; 105: 15671572.
10. Brevetti G, Silvestro A, Schiano V, Chiariello M. endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation. 2003; 108: 20932098.
11. Chan SY, Mancini GBJ, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol. 2003; 42: 10371043.
12. Fathi R, Haluska B, Isbel N, Short L, Marwick TH. The relative importance of vascular structure and function in predicting cardiovascular events J Am Coll Cardiol. 2004; 43: 616623.
13. Shimbo D, Grahame-Clarke C, Miyake Y, Rodriguez C, Sciacca R, Di Tullio M, Boden-Albala B, Sacco RL, Homma S. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis. June 5, 2006. DOI: 10.1016/j.atherosclerosis.2006.05.005. Available at: http://linkinghub.elsevier.com. Accessed April 18, 2007.
14. Yeboah J, Crouse JR, Hsu F-C, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation. 2007; 115: 23902397.
15. Anderson TJ, Roberts AC, Hildebrand K, Conradson HE, Jones C, Bridge P, Edworthy S, Lonn E, Verma S, Charbonneau F. The fate of endothelial function testing: rationale and design of the Firefighters and Their Endothelium (FATE) study. Can J Cardiol. 2003; 19: 6166.[Medline] [Order article via Infotrieve]
16. Juonala M, Viikari JS, Laitinen T, Marniemi J, Helenius H, Ronnemaa T, Raitakari OT. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the Cardiovascular Risk in YOUNG FINNS study. Circulation. 2004; 110: 29182923.
17. Vita JA, Keaney JF Jr, Larson MG, Keyes MJ, Massaro JM, Lipinska I, Lehman BT, Fan S, Osypiuk E, Wilson PWF, Vasan RS, Mitchell GF, Benjamin EJ. Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study. Circulation. 2004; 110: 36043609.
18. Mitchell GF, Parise H, Vita JA, Larson Mg, Warner E, Keaney JF Jr, Keyes MJ, Levy D, Vasan RS, Benjamin EJ. Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. Hypertension. 2004; 44: 134139.
19. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacob DR Jr, Kronmal R, Liu K, Nelson JC, OLeary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002; 156: 871881.
20. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002; 40: 505510.
This article has been cited by other articles:
![]() |
M. Elliott Commentary on Viewpoint: Exercise and cardiovascular risk reduction: Time to update the rationale for exercise? J Appl Physiol, August 1, 2008; 105(2): 776 - 776. [Full Text] [PDF] |
||||
![]() |
S. M. Shenouda and J. A. Vita Effects of Flavonoid-Containing Beverages and EGCG on Endothelial Function J. Am. Coll. Nutr., August 1, 2007; 26(4): 366S - 372S. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |